Related Experiment Video
Updated: Mar 22, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
13.2K
Developments in urologic oncology «OncoForum»: The best of 2015
F Gómez-Veiga1, A Alcaraz-Asensio2, J Burgos-Revilla3
1Servicio de Urología, Hospital Universitario de Salamanca, Grupo de Investigación Traslacional de Urología (GITUR), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.
Actas Urologicas Espanolas
|April 11, 2016
Summary
Recent advancements in urologic oncology offer new treatment options for advanced renal cancer and metastatic castration-resistant prostate cancer. Genetic profiles may guide bladder cancer therapy, improving clinical practice and patient outcomes.
Area of Science:
- Urologic Oncology
- Medical Oncology
- Cancer Research
Background:
- Review of recent oncologic urology evidence for prostate, renal, and bladder tumors.
- Analysis of clinical practice impact and future treatment regimens.
Purpose of the Study:
- To synthesize the latest evidence in urologic oncology.
- To analyze the impact of new findings on clinical practice.
- To explore future treatment strategies for urologic malignancies.
Main Methods:
- Review of abstracts from major 2015 congresses (EAU, AUA, ASCO, ESMO, ASTRO).
- Selection based on high evaluations by the OncoForum committee.
- Focus on prostate, renal, and bladder cancers.
Main Results:
- Cabozantinib identified as a potential second-line treatment for advanced renal cancer.
- Genetic expression profiling may predict neoadjuvant therapy response in muscle-invasive bladder cancer.
- Chemotherapy addition to androgen deprivation in metastatic castration-resistant prostate cancer showed reduced progression risk and improved PSA response.
Conclusions:
- New second-line treatment options for renal cancer have emerged.
- Enzalutamide demonstrated benefits in delaying symptomatic disease and improving overall survival in metastatic castration-resistant prostate cancer.
- Genetic markers show promise for personalized neoadjuvant therapy in urothelial tumors.
